iTeos Therapeutics (ITOS) Investor Presentation - Slideshow

iTeos Therapeutics internal data periphery, in Monotherapy and in Combination with an anti-PD1 EOS-448 monotherapy (400mg) GSK partnership ideal collaboration Combined capabilities and portfolios to accelerate and expand development Strategic Importance Key Collaboration Terms ● iTeos retains full independence beyond TIGIT partner for EOS-448 non-squamous NSCLC (N=243) First wave of development underway in large indications U.S. annual incidence 1L NSCLC PD-L1 High 2. Additional novel doublets beyond PD-1 * ...